High-tech imaging reveals details about rare eye disorder
Discovery sets the stage for development of new therapies to treat vitelliform macular dystrophy
- Date:
- July 28, 2022
- Source:
- NIH/National Eye Institute
- Summary:
- Using a new imaging technique, researchers have determined that retinal lesions from vitelliform macular dystrophy (VMD) vary by gene mutation. Addressing these differences may be key in designing effective treatments for this and other rare diseases.
- Share:
Using a new imaging technique, researchers from the National Eye Institute have determined that retinal lesions from vitelliform macular dystrophy (VMD) vary by gene mutation. Addressing these differences may be key in designing effective treatments for this and other rare diseases. NEI is part of the National Institutes of Health.
"The NEI's long-term investment in imaging technology is changing our understanding of eye diseases," said NEI Director Michael F. Chiang, M.D. "This study is just one example of how improved imaging can reveal subtle details about pathology in a rare eye disease that can inform the development of therapeutics."
VMD is an inherited genetic disease that causes progressive vision loss through degeneration of the light-sensing retina. Genes implicated in VMD include BEST1, PRPH2, IMPG1, and IMPG2. Depending on the gene and mutation, age of onset and severity vary widely. All forms of the disease have in common a lesion in the central retina (macula) that looks like an egg yolk and is a build-up of toxic fatty material called lipofuscin. VMD affects about 1 in 5,500 Americans and there is currently no treatment for this condition.
Johnny Tam, Ph.D., head of the NEI Clinical and Translational Imaging Unit, used multimodal imaging to evaluate the retinas of patients with VMD at the NIH Clinical Center. Tam's multimodal imaging uses adaptive optics -- a technique that employs deformable mirrors to improve resolution -- to view live cells in the retina, including the light-sensing photoreceptors, retinal pigment epithelial (RPE) cells, and blood vessels in unprecedented detail.
Tam and his team collaborated with clinicians at the NEI Eye Clinic to characterize 11 participants using genetic testing and other clinical assessments, and then evaluated their retinas using multimodal imaging. Assessment of cell densities (photoreceptors and RPE cells) near VMD lesions revealed differences in cell density according to the various mutations. IMPG1 and IMPG2 mutations had a greater effect on photoreceptor cell density than RPE cell density. The opposite was true with PRPH2 and BEST1 mutations. In participants with only one affected eye, the researchers noted similar effects on cell density in the unaffected eye, despite lacking lesions.
Tam is using multimodal imaging on a variety of other rare retinal diseases and more common ones including age-related macular degeneration.
Story Source:
Materials provided by NIH/National Eye Institute. Note: Content may be edited for style and length.
Journal Reference:
- Tao Liu, Nancy Aguilera, Andrew J. Bower, Joanne Li, Ehsan Ullah, Alfredo Dubra, Catherine Cukras, Brian P. Brooks, Brett G. Jeffrey, Robert B. Hufnagel, Laryssa A. Huryn, Wadih M. Zein, Johnny Tam. Photoreceptor and Retinal Pigment Epithelium Relationships in Eyes With Vitelliform Macular Dystrophy Revealed by Multimodal Adaptive Optics Imaging. Investigative Opthalmology & Visual Science, 2022; 63 (8): 27 DOI: 10.1167/iovs.63.8.27
Cite This Page: